Fig 1. Changes of plasma HBV DNA load in HIV/HBV-coinfected patients with lamivudine-resistant HBV (n = 33) or lamivudine-susceptible HBV (n = 56) who were on tenofovir-containing combination antiretroviral therapy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.